Using <i>N</i>‐Nitrosodiethanolamine (<scp>NDELA</scp>) and <i>N</i>‐Nitrosopiperidine (<scp>NPIP</scp>) Transgenic Rodent Gene Mutation Data and Quantum Mechanical Modeling to Derive Potency‐Based Acceptable Intakes for <scp>NDSRIs</scp> Lacking Rob

Acceptable intake (AI) limits for nitrosamine drug substance related impurities (NDSRIs) that lack carcinogenicity data could be estimated from mutagenic potency relative to anchor nitrosamines with carcinogenicity data. This approach integrates points of departure (PoDs) derived from in vivo mutagenicity studies with in silico predictions generated by a validated quantum-mechanical (QM) model. N-nitrosodiethanolamine (NDELA) and N-nitrosopiperidine (NPIP), with AIs derived from robust carcinogenicity data, were tested in the transgenic rodent (TGR) gene mutation assay. Liver mutant frequency and benchmark dose (BMD) modeling provided a suitable, robust, and precise PoD metric. BMD confidence intervals (CIs) calculated from mutant frequency expanded the potency range of previously reported BMD CIs for other anchor nitrosamines. Cancer-protective AIs for mutagenic NDSRIs can be pragmatically calculated on a potency basis by comparing their lower bound TGR BMD CIs with the BMD CIs and AIs derived from model/anchor nitrosamines that have results for in vivo gene mutation and cancer bioassays. In vivo modeling was supported by the Computer-Aided Discovery and RE-design (CADRE) program, a validated QM model for predicting NDSRI carcinogenic potency based on the underlying mechanism of mutagenicity. CADRE distinguished between anchor nitrosamines N-nitrosodiethylamine (NDEA) and N-nitrosodimethylamine (NDMA) and the less potent NDELA and NPIP. Scrutiny of underlying reactivity indices and relevant physicochemical properties rationalized the observed trend in metabolic activity and thus predicted carcinogenic potency. Leveraging the in vivo-in silico approach is valuable in gaining confidence in the proposed AIs, whereby the QM model serves as mechanistic validation of in vivo results.

Authors

Institutions

Publication Details

Journal
Environmental and Molecular Mutagenesis
Published
2025-04-01
DOI
https://doi.org/10.1002/em.70012
Citations
3
Primary Topic
Water Treatment and Disinfection
Type
article
Field-Weighted Citation Impact
3.60
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Using N‐Nitrosodiethanolamine (NDELA) and N‐Nitrosopiperidine (NPIP) Transgenic Rodent Gene Mutation Data and Quantum Mechanical Modeling to Derive Potency‐Based Acceptable Intakes for NDSRIs Lacking Rob

Adelina Voutchkova‐Kostal, Gregory R. Ott, George E. Johnson, Jason M. Roper et al.
3 citations
Environmental and Molecular Mutagenesis
Water Treatment and Disinfection
3.60
article

Using N‐Nitrosodiethanolamine (NDELA) and N‐Nitrosopiperidine (NPIP) Transgenic Rodent Gene Mutation Data and Quantum Mechanical Modeling to Derive Potency‐Based Acceptable Intakes for NDSRIs Lacking Rob

Adelina Voutchkova‐Kostal, Gregory R. Ott, George E. Johnson, Jason M. Roper, Jakub Kostal, Raphael Nudelman, Troy Griffin, Valerie Niddam‐Hildesheim
article en
3 citations

Abstract

Acceptable intake (AI) limits for nitrosamine drug substance related impurities (NDSRIs) that lack carcinogenicity data could be estimated from mutagenic potency relative to anchor nitrosamines with carcinogenicity data. This approach integrates points of departure (PoDs) derived from in vivo mutagenicity studies with in silico predictions generated by a validated quantum-mechanical (QM) model. N-nitrosodiethanolamine (NDELA) and N-nitrosopiperidine (NPIP), with AIs derived from robust carcinogenicity data, were tested in the transgenic rodent (TGR) gene mutation assay. Liver mutant frequency and benchmark dose (BMD) modeling provided a suitable, robust, and precise PoD metric. BMD confidence intervals (CIs) calculated from mutant frequency expanded the potency range of previously reported BMD CIs for other anchor nitrosamines. Cancer-protective AIs for mutagenic NDSRIs can be pragmatically calculated on a potency basis by comparing their lower bound TGR BMD CIs with the BMD CIs and AIs derived from model/anchor nitrosamines that have results for in vivo gene mutation and cancer bioassays. In vivo modeling was supported by the Computer-Aided Discovery and RE-design (CADRE) program, a validated QM model for predicting NDSRI carcinogenic potency based on the underlying mechanism of mutagenicity. CADRE distinguished between anchor nitrosamines N-nitrosodiethylamine (NDEA) and N-nitrosodimethylamine (NDMA) and the less potent NDELA and NPIP. Scrutiny of underlying reactivity indices and relevant physicochemical properties rationalized the observed trend in metabolic activity and thus predicted carcinogenic potency. Leveraging the in vivo-in silico approach is valuable in gaining confidence in the proposed AIs, whereby the QM model serves as mechanistic validation of in vivo results.

Environmental and Molecular MutagenesisVol. 66(4)
Swansea University (GB), Teva Pharmaceuticals (Israel) (IL), Teva Pharmaceuticals (United States) (US)
Good health and well-being
Openalex Percentile: Top 8%
Water Treatment and Disinfection
3.60
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.